Trial reportJournal of human hypertension2026
Cost-effectiveness of the simplified multicomponent primary care management of cardiovascular risk in Tibet, China: a within-trial and modeled economic evaluation.
Trial report in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The Simplified Cardiovascular Management Program (SimCard), a cluster-randomized controlled trial conducted in Tibet, China, demonstrated significant reduction in systolic blood pressure (SBP) compared to usual care among people with or at high risk of developing cardiovascular diseases (CVD). This study conducted a comprehensive economic evaluation for within-trial incremental cost per mmHg reduction in SBP at 12 months and per Quality-Adjusted Life Year (QALY) gained over the 10-year timeframe through a Markov-based CVD model. We reported expenses in 2023 CNY, using China's 2023 per-capita gross domestic product of CNY 89,358 as the cost-effectiveness threshold. We performed both one-way and probabilistic sensitivity analyses. During the trial period, the intervention group experienced a greater reduction in SBP, with a mean difference of 4.37 mmHg (95% CI: 1.32-7.42) compared to the usual care group. The Incremental Cost-Effectiveness Ratio (ICER) was CNY 101 (95% CI: 85-137) per mmHg reduction in SBP. In the 10-year modeled cost-effectiveness analysis, QALYs were higher in the intervention group by 0.11 (95% CI: 0.02-0.22) compared to the control group. The intervention had superior outcomes at similar costs (¥19,439 for the intervention group compared to ¥19,622 for the control group). This outcome remained robust across all sensitivity analyses The SimCard intervention was cost saving in preventing CVD among individuals at high risk in resource-constrained settings in China. Our findings highlight significant economic and health benefits of the intervention in Tibet, China, potentially generalizable to similar settings in other low- and middle-income countries.
Indexed as
Identifiers
41361508What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.